Olorofim Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Olorofim comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Invasive Fungal Infections. Most recent publication: Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study., J Antimicrob Chemother, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
    Maertens JA, Thompson GR, Spec A, et al. · Lancet Infect Dis · 2025
    PubMed: PMID 40541222 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections
  2. Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.
    Maertens J, Chen SCA, Thompson GR, et al. · J Antimicrob Chemother · 2026
    PubMed: PMID 41914555 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections
  3. Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.
    Cornelissen K, Rex JH, Zinzi D, et al. · Antimicrob Agents Chemother · 2026
    PubMed: PMID 42008658 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections

Publications by year

2025–2026: 3 publications.

2025
1
2026
2

Publications by indication

Invasive Fungal Infections (3)

  • Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.
    J Antimicrob Chemother · 2026 · PMID 41914555 · NCT03583164
  • Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.
    Antimicrob Agents Chemother · 2026 · PMID 42008658 · NCT03583164
  • Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
    Lancet Infect Dis · 2025 · PMID 40541222 · NCT03583164

Publications by journal

  • Lancet Infect Dis1 paper
  • J Antimicrob Chemother1 paper
  • Antimicrob Agents Chemother1 paper

All Olorofim publications (3)

2026 (2 papers)

  1. Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.
    Maertens J, Chen SCA, Thompson GR, et al. · J Antimicrob Chemother · 2026 · Derived
    PubMed: PMID 41914555 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections
  2. Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.
    Cornelissen K, Rex JH, Zinzi D, et al. · Antimicrob Agents Chemother · 2026 · Derived
    PubMed: PMID 42008658 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections

2025 (1 paper)

  1. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
    Maertens JA, Thompson GR, Spec A, et al. · Lancet Infect Dis · 2025 · Derived
    PubMed: PMID 40541222 · NCT03583164 (FORMULA-OLS) · Invasive Fungal Infections

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 14 May 2026 22:12:09 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).